Oxford BioDynamics (OBD) AI Stock Analysis

• Market Cap: £10.73M
• Dividend Yield: N/A
• Average Volume (3M): 21.87M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.95
• Revenue Growth: 72.17%
• EPS Growth: 79.03%
• Country: UK
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 4,290,911,000
• 10 Day Avg. Volume: 50,883,470
• 30 Day Avg. Volume: 21,870,725
• PEG Ratio: <0.01
• Price to Book (P/B): 5.90
• Price to Sales (P/S): 6.02
• P/FCF Ratio: -0.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): >-0.01
• Revenue Forecast (FY): £2.32M

• Rating: 45 Neutral
• Price Target: 0.24p ▲(1.67% Upside)
• Action: Upgraded Date: 02/05/26
• Date: Action: Upgraded 02/05/26

The score is primarily constrained by weak financial performance—ongoing losses, high leverage, and worsening free cash flow trends. Technical indicators provide some near-term support (price above 20/50-DMAs and positive MACD), but longer-term moving averages remain overhead. Valuation is also pressured by negative earnings (negative P/E) and no stated dividend yield.

Positive Factors

Proprietary EpiSwitch platform

OBD’s proprietary EpiSwitch platform represents a durable competitive asset: it enables differentiated epigenetic biomarker discovery and diagnostic development across oncology and autoimmune indications. Proprietary IP and a platform model support licensing, scalable test development and partner lock‑ins that can generate recurring long‑term revenues and high switching costs for collaborators.

Diversified revenue streams

The company generates revenue from contract research services, pharma/biotech partnerships, licensing the EpiSwitch technology and potential royalties. This mix combines project work with scalable licensing economics, reducing dependence on any single revenue source and improving resilience versus a pure product or single‑partner model over the medium term.

Strong top-line growth

Reported revenue growth (72.17% in the fundamentals) indicates accelerating commercial traction or expanded service/licensing activity. Sustained top‑line expansion supports scale economics and reinforces the platform’s market relevance, enabling continued R&D investment, broader validation studies and stronger negotiating leverage with strategic partners.

Negative Factors

Persistent unprofitability

Consistent negative profitability—net margin at -10.19% and negative gross/EBIT margins—shows the company has not yet converted revenue into sustainable earnings. Long‑running losses erode equity, increase dependence on external capital, and constrain the ability to self‑fund validation, commercialization and longer‑term strategic initiatives without dilution or higher financing costs.

High financial leverage

A debt-to-equity ratio of 4.58 signals heavy leverage, raising refinancing and interest‑rate risk while reducing strategic flexibility. For a biotech focused on platform development, elevated debt burden can force prioritization of near‑term cash management over R&D or commercialization, increasing execution risk and vulnerability to adverse market conditions.

Weak cash generation

Deteriorating cash generation—free cash flow down 33.93% and operating cash flow negative relative to net income—reflects poor cash conversion and potential runway pressure. Sustained negative operating cash flow heightens reliance on external funding, which can dilute shareholders, increase financing costs and complicate long‑term commercialization and scale‑up plans.

Oxford BioDynamics Business Overview & Revenue Model

Company Description

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

How the Company Makes Money

Oxford BioDynamics generates revenue through a combination of biomarker discovery services, partnerships with pharmaceutical and biotechnology companies, and the commercialization of its proprietary EpiSwitch technology. Key revenue streams include contract research services, which provide clients with tailored biomarker analysis and support for drug development; licensing agreements for its EpiSwitch platform, enabling partners to utilize its technology in their own research and diagnostic products; and potential royalties from any commercialized tests developed in collaboration with strategic partners. The company has established collaborations with various academic institutions and industry players, which not only enhance its research capabilities but also create additional revenue opportunities through joint ventures and shared intellectual property.

Oxford BioDynamics Financial Statement Overview

Summary

Financial statements indicate significant weakness: persistent losses (net margin -10.19%) with negative gross/EBIT margins, high leverage (debt-to-equity 4.58) and negative ROE, and deteriorating cash generation (free cash flow growth -33.93%) alongside cash flow challenges.

Income Statement

Oxford BioDynamics shows a consistent pattern of negative profitability with a net profit margin of -10.19% in the latest year. Despite a revenue growth rate of 22.21%, the company struggles with negative gross and EBIT margins, indicating challenges in managing costs and achieving operational efficiency.

Balance Sheet

The company's balance sheet reveals high leverage with a debt-to-equity ratio of 4.58, indicating significant reliance on debt financing. The return on equity is negative, reflecting ongoing losses and potential risks to equity holders. The equity ratio is low, suggesting limited asset backing by equity.

Cash Flow

Cash flow analysis shows a negative free cash flow growth rate of -33.93% and a high free cash flow to net income ratio of 1.00, indicating that cash flow is closely aligned with net losses. The operating cash flow to net income ratio is negative, highlighting cash flow challenges.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	1.09M	636.00K	510.00K	154.00K	341.00K
Gross Profit	-6.15M	289.00K	266.00K	116.00K	-557.00K
EBITDA	-9.80M	-10.27M	-9.84M	-6.16M	-6.43M
Net Income	-11.15M	-11.57M	-10.83M	-6.71M	-6.68M
Balance Sheet
Total Assets	8.09M	12.11M	16.13M	11.34M	15.38M
Cash, Cash Equivalents and Short-Term Investments	1.39M	2.83M	5.25M	999.00K	4.34M
Total Debt	5.11M	5.74M	6.44M	6.14M	6.59M
Total Liabilities	6.97M	7.75M	10.07M	8.76M	8.69M
Stockholders Equity	1.12M	4.36M	6.05M	2.59M	6.68M
Cash Flow
Free Cash Flow	-7.73M	-10.77M	-9.01M	-6.08M	-9.01M
Operating Cash Flow	-7.71M	-10.17M	-8.29M	-5.18M	-5.92M
Investing Cash Flow	756.00K	-1.49M	-691.00K	1.25M	2.83M
Financing Cash Flow	6.52M	8.25M	13.42M	2.56M	-804.00K

Oxford BioDynamics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.27, and below the 200-day MA of 0.37, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.84 is Neutral, neither overbought nor oversold. The STOCH value of 16.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.

Oxford BioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APTA	52 Neutral	£23.60M	-6.25	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXI	51 Neutral	£7.07M	-4.10	-15.57%	―	13.32%	55.07%
GENF	47 Neutral	£9.38M	-3.80	-648.46%	―	―	―
OBD	45 Neutral	£10.73M	-0.26	-407.49%	―	72.17%	79.03%
SBTX	44 Neutral	£24.15M	-28.24	-11.24%	―	283.74%	78.57%
FAB	44 Neutral	£17.19M	-9.55	-164.37%	―	-11.43%	23.40%

Oxford BioDynamics Corporate Events

Oxford BioDynamics to Showcase EpiSwitch Orion at PMWC 2026

Oxford BioDynamics will showcase its newly launched EpiSwitch Orion platform at the Precision Medicine World Conference 2026 in Silicon Valley, with Chief Data Officer Ewan Hunter presenting how the technology converts static DNA data into actionable insights for targeted therapies. The appearance at a high-profile industry forum known as the “Davos of Precision Medicine” underlines the company’s ambition to position EpiSwitch Orion and its AI-driven 3D genomics knowledgebase as a key tool for pharmaceutical, biotech and academic partners seeking to better stratify patients and accelerate precision medicine in cancer, autoimmune and neurological diseases.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.24 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics appoints new adviser to bolster AIM market support

Oxford BioDynamics, a UK-based precision clinical diagnostics company listed on AIM, specializes in blood-based tests built on its EpiSwitch 3D genomics platform to improve early disease detection and therapy selection. Its commercial portfolio currently includes high-accuracy tests for prostate cancer screening and predicting responses to checkpoint inhibitor treatments, and it is extending this technology across multiple therapeutic areas.

The company has appointed Singer Capital Markets Advisory as its new Nominated Adviser and Broker, a move that may strengthen its capital markets support and investor engagement on London’s AIM market. The change in adviser could enhance Oxford BioDynamics’ market positioning and access to funding as it advances development and commercialization of its expanding suite of EpiSwitch-based diagnostic tests.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.30 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics AGM Resolutions Passed Amid Shareholder Dissent on Pay and Governance

Oxford BioDynamics announced that all resolutions at its Annual General Meeting were passed, including the approval of financial statements, director elections and re-elections, auditor reappointment, share allotment authorities and the power to buy back its own shares, as well as the disapplication of pre-emption rights for certain capital raisings. However, a significant minority of shareholders opposed the remuneration report and the re-election of non-executive director Dr David Holbrook, prompting the board to commit to further consultation with investors, a move that underscores ongoing shareholder scrutiny of governance and pay at the AIM-listed diagnostics group.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.26 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Board Veteran Steps Down as Major Shareholder Retains Influence

Oxford BioDynamics has announced that long-serving non-executive director Stephen Diggle has stepped down from the board with immediate effect, in line with previously signalled plans and corporate governance practice after nine years in the role. While Diggle departs the board, his firm Vulpes Investment Management remains the company’s largest shareholder and will nominate a new non-executive director in due course, ensuring continued influence over governance and strategic direction at a time when the diagnostics specialist is commercialising its EpiSwitch-based tests and seeking to strengthen its market position.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.26 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Publishes 2025 Annual Report and Sets Date for AGM

Oxford BioDynamics has published its annual report and accounts for the year ended 30 September 2025, making the document available electronically on its website and dispatching hard copies, including the notice of its upcoming annual general meeting, to shareholders. The AGM is scheduled to take place in Oxford on 26 January 2026, providing investors with a formal opportunity to review the company’s performance and strategy as it continues to commercialise and expand its portfolio of precision genomic diagnostic tests.

The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.23 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Reports Strong Growth and Strategic Partnerships in 2025

Oxford BioDynamics Plc announced its preliminary results for the year ending September 2025, highlighting significant growth in its EpiSwitch® Prostate Screening Test orders and a successful £7 million fundraising effort. The company has made strategic advancements, including a partnership with Google Cloud and ongoing discussions for third-party collaborations, positioning itself for further growth and increased shareholder value.

The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics to Announce Year-End Financial Results

Oxford BioDynamics Plc announced that it will release its financial results for the year ending 30 September 2025 on 16 December 2025. This announcement highlights the company’s ongoing commitment to transparency and may impact its market positioning by providing stakeholders with insights into its financial health and operational progress.

The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Reports Record Sales Amidst Screening Recommendations

Oxford BioDynamics Plc announced that the recent UK National Screening Committee’s draft recommendation on prostate cancer screening does not directly affect its EpiSwitch PSE test. Despite this, the company has reported six consecutive months of record sales for the PSE test in the US and private healthcare in the UK, indicating strong market performance and growth potential.

The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.